Quiver Bioscience advances Nav1.7 antisense therapy as pain drug innovation heats up
Chronic pain needs safer drugs. Quiver’s NIH-backed Nav1.7 ASO bet could test whether genetics can beat opioid-era limits.
Pharma & Biotech
Pharma & Biotech
Does VAS-101 solve a long-standing delivery problem in curcumin-based osteoarthritis treatment?
Vascarta’s VAS-101 showed early knee osteoarthritis pain benefits. Read what the data changes, what remains unclear, and what to watch next.
Pharma & Biotech
Nocion Therapeutics reveals new pain data: Is a platform pivot underway?
Find out how Nocion’s nocions™ could change pain treatment by silencing activated neurons without opioids. New preclinical data inside.